Celine Halioua

Celine Halioua is the founder and CEO of Loyal, a San Francisco biotech company developing the first FDA-approved drug for lifespan extension - starting with dogs. Born in Austin, Texas to a Moroccan mother and German father, she studied neuroscience at UT Austin and nanotechnology at Uppsala University before pursuing a DPhil at Oxford on the health economics of gene therapy. She left Oxford to join Laura Deming's Longevity Fund as Chief of Staff, then founded Loyal in 2019 at age 24. With $250M+ in total funding and the largest clinical trial ever conducted in animal health (1,300+ dogs across 70+ clinics), Loyal's lead drug LOY-002 has cleared FDA safety and efficacy hurdles - putting it on track to become the first longevity drug ever approved for any species.